Nitrous oxide (laughing gas) inhalation as an alternative to electroconvulsive therapy.
Brian Milne
Medical Hypotheses May 1, 2010 DOI: 10.1016/j.mehy.2009.11.021 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Intervention | Nitrous oxide |
| Key points | Proposes that nitrous oxide could substitute for ECT in treating psychiatric conditions due to shared mechanisms including sympathetic stimulation, endogenous opioid release, and seizure-like activity. |
Abstract
Electroconvulsive therapy (ECT) is used widely in the treatment of psychiatric conditions; however, its use is not without controversy with some recommending a moratorium on its clinical use. Complications and side effects of ECT include memory loss, injury, problems originating from sympathetic stimulation such as arrhythmias and myocardial ischemia and the risk of general anesthesia. Nitrous oxide (laughing gas) could potentially substitute for ECT as it shares some similar effects, has potential beneficial properties for these psychiatric patients and is relatively safe and easy to administer. Nitrous oxide induces laughter which has been described as nature's epileptoid catharsis which one might surmise would be beneficial for depression. It also produces a central sympathetic stimulation similar to ECT and causes release of endogenous opioid peptides, which are potential candidates for the development of antidepressant drugs. Nitrous oxide is also associated with seizure like activity itself. Administration of nitrous oxide as a substitute for ECT is eminently feasible and could be given in a series of treatments similar to ECT therapy.
Citations in the library
Cited by 4
- Ketamine and electroconvulsive therapy for severe depression: A network meta-analysis of efficacy and safety. Journal of Psychiatric Research July 1, 2024
- Rapid antidepressant potential of nitrous oxide: current state and major questions. Molecular Psychiatry June 1, 2026
- Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents. Journal of the Neurological Sciences May 15, 2020
- Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy. Frontiers in Psychiatry 2015